Department of Neurology, University of Iowa Hospitals and Clinics, Iowa City, Iowa, USA.
Neuroscience, Clinical Effectiveness and Public Health Research Group, Universidad Cientifica del Sur, Lima, Peru.
J Neurointerv Surg. 2023 Dec 21;15(e3):e460-e467. doi: 10.1136/jnis-2022-019975.
There is limited evidence on the indication and role of mechanical thrombectomy (MT) in patients with distal medium-vessel occlusions (DMVOs). The aim of this systematic review and meta-analysis was to evaluate all the evidence available on the efficacy and safety of MT techniques (stent retriever, aspiration) in primary and secondary DMVOs.
Five databases were searched from inception to January 2023 for studies of MT in primary and secondary DMVOs. Outcomes of interest included favorable functional outcome (90-day modified Rankin scale (mRS) 0-2), successful reperfusion (modified Thrombolysis in Cerebral Infarction (mTICI) 2b-3), symptomatic intracerebral hemorrhage (sICH), and 90-day mortality. Prespecified subgroup meta-analyses according to the specific MT technique and to the vascular territory (distal M2-M5, A2-A5, P2-P5) were also performed.
A total of 29 studies with 1262 patients were included. For primary DMVOs (n=971 patients), pooled rates of successful reperfusion, favorable outcome, 90-day mortality and sICH were 84% (95% confidence interval (CI) 76 to 90%), 64% (95% CI 54 to 72%), 12% (95% CI 8 to 18%), and 6% (95% CI 4 to 10%), respectively. For secondary DMVOs (n=291 patients), pooled rates of successful reperfusion, favorable outcome, 90-day mortality and sICH were 82% (95% CI 73 to 88%), 54% (95% CI 39 to 69%), 11% (95% CI 5 to 20%), and 3% (95% CI 1 to 9%), respectively. Subgroup analyses by MT technique and by vascular territory showed no differences in primary and secondary DMVOs.
Our findings suggest that MT using aspiration or stent retriever techniques appears to be effective and safe in primary and secondary DMVOs. However, given the level of evidence of our results, further confirmation in well-designed randomized controlled trials is needed.
关于机械取栓(MT)在远端中等血管闭塞(DMVOs)患者中的适应证和作用,目前证据有限。本系统评价和荟萃分析的目的是评估原发性和继发性 DMVOs 中 MT 技术(支架取栓器、抽吸)的有效性和安全性的所有现有证据。
从创建至 2023 年 1 月,在五个数据库中搜索 MT 治疗原发性和继发性 DMVOs 的研究。感兴趣的结局包括良好的功能结局(90 天改良 Rankin 量表(mRS)0-2)、成功再灌注(改良脑梗死溶栓(mTICI)2b-3)、症状性颅内出血(sICH)和 90 天死亡率。还根据特定的 MT 技术和血管区域(远端 M2-M5、A2-A5、P2-P5)进行了预设的亚组荟萃分析。
共纳入 29 项研究,共 1262 例患者。对于原发性 DMVOs(n=971 例患者),成功再灌注、良好结局、90 天死亡率和 sICH 的汇总率分别为 84%(95%置信区间[CI]76-90%)、64%(95% CI 54-72%)、12%(95% CI 8-18%)和 6%(95% CI 4-10%)。对于继发性 DMVOs(n=291 例患者),成功再灌注、良好结局、90 天死亡率和 sICH 的汇总率分别为 82%(95% CI 73-88%)、54%(95% CI 39-69%)、11%(95% CI 5-20%)和 3%(95% CI 1-9%)。按 MT 技术和血管区域进行的亚组分析显示,原发性和继发性 DMVOs 之间没有差异。
我们的研究结果表明,使用抽吸或支架取栓器技术的 MT 在原发性和继发性 DMVOs 中似乎是有效和安全的。然而,鉴于我们研究结果的证据水平,还需要在精心设计的随机对照试验中进一步证实。